Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) traded up 12.1% on Friday . The stock traded as high as $1.46 and last traded at $1.39. 532,907 shares traded hands during trading, an increase of 113% from the average session volume of 249,729 shares. The stock had previously closed at $1.24.

Several analysts have recently weighed in on the company. Maxim Group set a $5.00 price objective on Viking Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 10th. ValuEngine raised Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective (up previously from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th.

The firm has a 50 day moving average of $1.20 and a 200 day moving average of $1.20. The stock’s market cap is $38.50 million.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.02). On average, equities research analysts expect that Viking Therapeutics, Inc. will post ($0.82) earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Viking Therapeutics stock. Virtu KCG Holdings LLC bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 114,507 shares of the biotechnology company’s stock, valued at approximately $124,000. Virtu KCG Holdings LLC owned 0.48% of Viking Therapeutics at the end of the most recent quarter. Institutional investors own 5.67% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.